CHLORDIAZACHEL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CHLORDIAZACHEL (CHLORDIAZACHEL).
Chlordiazepoxide is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion influx, hyperpolarization of neurons, and decreased neuronal excitability. This produces anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
| Metabolism | Chlordiazepoxide is metabolized in the liver primarily by CYP3A4 and CYP2D6 enzymes. Its active metabolites include desmethylchlordiazepoxide, demoxepam, and nordazepam. |
| Excretion | Renal: 50-70% as metabolites (mainly oxazepam and desmethylchlordiazepoxide); biliary/fecal: 10-20% as glucuronide conjugates; 1-2% excreted unchanged. |
| Half-life | Parent: 5-30 hours (mean 15 hours); active metabolite desmethylchlordiazepoxide: 10-20 hours; further metabolite demoxepam: 24-96 hours; clinical context: causes drug accumulation with chronic dosing, especially in elderly or hepatic impairment. |
| Protein binding | 90-98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.5-0.8 L/kg; high Vd indicates extensive tissue distribution, with accumulation in adipose and brain tissue. |
| Bioavailability | Oral: 90-100% (well absorbed); IM: 80-100% (but variable due to precipitation at injection site); IV: 100%. |
| Onset of Action | Oral: 30-60 minutes (full anxiolytic effect 1-2 hours); intramuscular: 15-30 minutes (but erratic absorption); intravenous: 1-5 minutes (for acute agitation or alcohol withdrawal). |
| Duration of Action | Oral: 6-12 hours (anxiolytic); IM/IV: 2-4 hours (due to redistribution). Clinical note: duration prolonged with repeated dosing due to long-acting metabolites; risk of sedation and accumulation in elderly. |
Initial: 5-10 mg orally 3-4 times daily; for severe anxiety, up to 25 mg 4 times daily. IM: 50-100 mg initially, then 25-50 mg 3-4 times daily if needed.
| Dosage form | CAPSULE |
| Renal impairment | GFR 10-50 mL/min: administer 50-100% of usual dose; GFR <10 mL/min: administer 25-50% of usual dose. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce by 75%. |
| Pediatric use | Children 6-12 years: 5 mg orally 2-4 times daily, max 30 mg/day. Not recommended under 6 years. |
| Geriatric use | Initial: 5 mg orally 1-2 times daily, increase cautiously; reduce total daily dose by 50% compared to younger adults. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CHLORDIAZACHEL (CHLORDIAZACHEL).
| Breastfeeding | Excreted in breast milk; M/P ratio 0.25-0.5. Potential for infant sedation, poor feeding. Avoid breastfeeding or use alternative therapy. |
| Teratogenic Risk | First trimester: Increased risk of cleft lip/palate (OR 1.8-2.5). Second/third trimester: Risk of neonatal withdrawal, hypotonia, respiratory depression. Avoid in pregnancy unless benefit justifies risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
| Serious Effects |
["Hypersensitivity to chlordiazepoxide or any benzodiazepine","Severe respiratory insufficiency","Sleep apnea syndrome","Severe hepatic impairment","Myasthenia gravis","Acute narrow-angle glaucoma","Concomitant use with ketoconazole, itraconazole, or other strong CYP3A4 inhibitors"]
| Precautions | ["Risk of dependence and withdrawal reactions","Potential for abuse and addiction","Respiratory depression, especially with concomitant CNS depressants","Central nervous system depressant effects, caution with impaired hepatic or renal function","Paradoxical reactions (e.g., agitation, aggression) in psychiatric patients","Suicidal ideation and behavior","Use in pregnancy: risk of neonatal sedation and withdrawal","Elderly patients: increased sensitivity and risk of falls"] |
| Food/Dietary |
Loading safety data…
| Maternal: liver function tests, CBC, signs of sedation or ataxia. Fetal/neonatal: ultrasound for anomalies (if first trimester exposure), monitoring for withdrawal symptoms (jitteriness, feeding difficulties) after delivery. |
| Fertility Effects | Possible disruption of menstrual cycle and ovulation due to neuroendocrine effects. Reversible upon discontinuation. |
| Avoid alcohol. No specific food interactions; take with or without food. Limit caffeine if it worsens symptoms. |
| Clinical Pearls | CHLORDIAZACHEL is a combination of chlordiazepoxide (benzodiazepine) and clidinium (anticholinergic). Used for peptic ulcer and irritable bowel syndrome. Monitor for CNS depression and anticholinergic effects (dry mouth, blurred vision, constipation). Avoid in glaucoma, urinary retention, and myasthenia gravis. Discontinue gradually to prevent withdrawal. |
| Patient Advice | Take exactly as prescribed; do not increase dose or duration. · Avoid alcohol and other CNS depressants. · May cause drowsiness; do not drive or operate machinery until effects are known. · Report bothersome side effects like constipation, dry mouth, or blurred vision. · Do not stop suddenly; taper under medical supervision. · Inform all healthcare providers you are taking this medication. |